Gene · 9582
APOBEC3B: apolipoprotein B mRNA editing enzyme catalytic subunit 3B
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. APOBEC3B: apolipoprotein B mRNA editing enzyme catalytic subunit 3B. Genes, record 9582. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/9582
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q9UH17 | DNA dC->dU-editing enzyme APOBEC-3B | 382 | 13 | Ensembl, GeneID, HGNC |
Source UniProt
Patents200
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4828972 A1 | 2026-10-28 | 37 | Q9UH17 | Espacenet |
| EP 4828972 A1 | 2026-10-28 | 582 | Q9UH17 | Espacenet |
| EP 4828972 A1 | 2026-10-28 | 631 | Q9UH17 | Espacenet |
| JP 2026525611 A | 2026-07-31 | 70 | Q9UH17 | Espacenet |
| JP 2026525612 A | 2026-07-31 | 503 | Q9UH17 | Espacenet |
| EP 4777618 A1 | 2026-07-22 | 37 | Q9UH17 | Espacenet |
| EP 4777618 A1 | 2026-07-22 | 582 | Q9UH17 | Espacenet |
| EP 4777618 A1 | 2026-07-22 | 631 | Q9UH17 | Espacenet |
| JP 2026116287 A | 2026-07-09 | 274 | Q9UH17 | Espacenet |
| EP 4762095 A1 | 2026-06-24 | 37 | Q9UH17 | Espacenet |
1 to 10 of 200
See all 200 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,186
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | APOBEC3B papers | Newest fiscal year |
|---|---|---|---|
| P01CA234228 | APOBEC Mutagenesis in Cancer | 44 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 26 | 2025 |
| T32CA009138 | Molecular, Genetic and Cellular Targets of Cancer Training Program | 20 | 2025 |
| T32AI083196 | Minnesota Training Program in Virology | 17 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 15 | 2025 |
| R37CA252081 | Molecular Mechanisms of APOBEC-Induced Mutagenesis in Cancer | 14 | 2025 |
| R35GM118047 | Structural studies of viral replication and invasion | 13 | 2025 |
| P30AI027763 | UCSF-Bay Area Center for AIDS Research | 10 | 2025 |
| ZIAES103266 | Genome-wide hypermutation and structural instability | 10 | 2025 |
| P30CA077598 | Cancer Center Support Grant | 9 | 2025 |
1 to 10 of 1,186Source NIH's project files
See all 1,186 nih grantsPapers1,875
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| APOBEC3 activity and DNA polymerase-ε deficiency are associated with distinct IDH1 R132 hotspot mutations. | Mol Oncol | 2026 | 42717521 | PubTator, text mining | PubMed |
| Fluorescence polarization-based fragment screen identifies inhibitors of APOBEC3A and APOBEC3B. | bioRxiv | 2026 | 42620011 | PubTator, text mining | PubMed |
| Association of APOBEC mutagenesis with stromal and endothelial niche remodeling and PCDH9-linked signaling alterations in colorectal cancer. | Front Immunol | 2026 | 42535079 | PubTator, text mining | PubMed |
| Distinct repair processes produce APOBEC-induced deletions, tandem substitutions, and complex mutations in yeast and human cells. | Proc Natl Acad Sci U S A | 2026 | 42520125 | PubTator, text mining | PubMed |
| Multiomic profiling links L1 retrotransposition to genomic instability and ecDNA in bladder cancer. | Nat Commun | 2026 | 42463649 | PubTator, text mining | PubMed |
| Collapsing retroviruses for efficient delivery of viro-toxic cargoes. | bioRxiv | 2026 | 42427788 | PubTator, text mining | PubMed |
| The regulatory mechanism and clinical significance of RNA editing in prostate cancer. | Curr Urol | 2026 | 42368672 | PubTator, text mining | PubMed |
| Full-length structure of the anti-viral and pro-tumor DNA deaminase APOBEC3B. | bioRxiv | 2026 | 42367898 | PubTator, text mining | PubMed |
| Shared diagnostic biomarkers in metabolic syndrome and coronary artery disease identified by integrated bioinformatics and machine learning. | Endocr Connect | 2026 | 42160392 | PubTator, text mining | PubMed |
| Identification of Immune-Related Diagnostic Genes and Subtypes of Active Ulcerative Colitis. | Iran J Allergy Asthma Immunol | 2026 | 42130146 | PubTator, text mining | PubMed |
1 to 10 of 1,875
See all 1,875 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/9582
GET https://conductscience.org/api/genes/v1/9582/patents?page=2